OOIR: Observatory of International Research

Papers

(The TQCC of Lancet Haematology is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Zanubrutinib-associated ecchymotic lesions	425
Correction to Lancet Haematol 2023; 10: e333–45	346
Optimising communication to patients with venous thromboembolism: development of a provider toolkit	219
Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?	191
Is there still a role for CNS prophylaxis in diffuse large B-cell lymphoma?	182
Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries	166
Towards reparatory measures: blood donation, health systems, and men who have sex with men	150
Correction to Lancet Haematol 2024; 11: e114–26	145
In the trenches	135
Prioritising health equity alongside donation safety – Authors' reply	129
Correction to Lancet Haematol 2023; published online Aug 28. https://doi.org/10.1016/S2352-3026(23)00164-3	127
MRD-guided treatment cessation in multiple myeloma	125
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial	118
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity?	106
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts	105
Blood cell defence against pathogens	99
Illegal blood trade as cause for blood shortages in public hospitals in northern Nigeria	99
Rituximab versus active surveillance in patients with follicular lymphoma	98
Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study	90
Call to action: equitable comprehensive care for patients with sickle cell disease in the USA	90
Eltrombopag–cyclosporin A in treating severe aplastic anaemia	82
Extensively distributed erythema nodosum in VEXAS syndrome	81
Correction to Lancet Haematol 2025; 12: e294–303	77
Production and supply of blood products in Brazil	76
International Society on Thrombosis and Haemostasis Congress 2023	75

Correction to Lancet Haematol 2023; 10: e433–44	75
Bedside art is good medicine	74
Be compliant or compromise?	74
Blood deserts: a vision to tackle blood inaccessibility	70
The HemeOncBuddy app—a new tool to keep up with the clinical trial storm	69
Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia	67
Artwork from trauma: the social life of medical data	67
Blinatumomab plus hyper-CVAD: the prelude to a new era in acute lymphocytic leukaemia	66
Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis	66
Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study	65
Update on SickleInAfrica: a collaborative and multidimensional approach to conduct research and improve health	65
Sickle cell disease in India: current status and progress	64
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study	63
Methodological challenges in the development of endpoints for myelofibrosis clinical trials	59
USAID's enduring impact on anaemia management must be preserved	59
Anaemia in a time of climate crisis	59
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study	58
Coexisting genetic abnormalities and thrombocytopenia	58
25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial	58
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective	57
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past	56
Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial	54
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, ran	54
Correction to Lancet Haematol 2024; 11: e310–11	53
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations	53
Oreofe Odejide—aiming to raise the bar in haematology care	52
Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatment	51
Correction to Lancet Haematol 2022; 9: e200–07	51
Universal health coverage for children with cancer	50
Correction to Lancet Haematol 2022; Published online July 27. https://doi.org/10.1016/S2352-3026(22)00206-X	50
Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond	50
Global effort to evacuate Ukrainian children with cancer and blood disorders who have been affected by war	49
Beyond maximum grade: advancing the measurement and analysis of adverse events in malignant haematology trials in the modern era	49
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study	49
[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial	48
Could improving mental health disorders help increase cancer survival?	47
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial	46
Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial	46
Efficacy or convenience? Subcutaneous blinatumomab as a promising new treatment for B-cell acute lymphoblastic leukaemia	42
Correction to Lancet Haematol 2024; 11: e521–29	42
Striking the right balance	42
2024 ASH Annual Meeting	41
Haematology and climate change	40
Patients first: improving toxicity assessment and reporting	40
Carfilzomib–lenalidomide–dexamethasone versus lenalidomide–dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label,	39
The challenge of defining the global burden of iron deficiency anaemia	39
Haemophilia—unparalleled progress but inadequate access	38
Secondary haematological malignancies	38
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study	38
A long-awaited benchmark in lymphomatoid granulomatosis	38

Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation	37
Should patients with haemophilia receive gene therapy?	36
Elotuzumab: no additional effect in patients with newly diagnosed multiple myeloma	36
Sickle cell disease—unity and patient-centred education	35
The rollercoaster of vaccine-induced immune thrombotic thrombocytopenia	34
Addressing inequity in access to palliative care for patients with non-malignant or benign haematological diseases	33
Thank you to our 2022 peer reviewers and an update on inclusion and diversity	33
Lakshmi Nayak: striving to contain the brain's deadliest killers	33
Reporting of trials with possible detrimental overall survival: a patient advocate perspective	33
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-lab	32
In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospecti	32
Acute myeloid leukaemia at the extremes	31
Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management	31
Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial	30
Comparison of international guideline recommendations for the diagnosis of pulmonary embolism	29
Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting Series	29
The Lancet Haematology at 10	29
The impact of patient ethnicity on haematopoietic cell transplantation outcome: a retrospective cohort study on the UK experience	29
Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial	29
Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 t	28
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study	28
Breaking sex biases: access for all in haemophilia care	28
Gene therapy in China: past, present, and future	27
Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma	27
Sovleplenib in immune thrombocytopenia	26
Thank you to The Lancet Haematology's peer reviewers in 2022	26
Can defibrotide prophylaxis prevent sinusoidal obstruction syndrome following haematopoietic stem-cell transplantation?	26
Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?	26
Life beyond blood disorders	26
Management of pregnancies with anti-K alloantibodies and the predictive value of anti-K titration testing	25
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group	25
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7)	25
Needles were the least of my worries	24
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow	24
Leprosy and leukaemia: an unexpected interaction	24
Acquired haemophilia in an Edo period Japanese surgical casebook	23
Virtual twins for personalised CAR T-cell therapy in myeloma	23
Making a case for disease-modifying agents in myelofibrosis	23
Melflufen in multiple myeloma: the conclusion matters	23
Don Thomas: leading the charge to bone marrow transplantation	23
A treatise on clinical trials	23
The effects of upward revision of haemoglobin thresholds for anaemia in blood donations	23
Clinical trial design change implementation for inclusive studies	22
Artificial intelligence in peripheral blood films: an evolving landscape	22
Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial	22
Monumen-TAL progress in the treatment of relapsed multiple myeloma	22
Ask, do not tell: consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe	22
Heavy menstrual blood loss in patients with von Willebrand disease: an unsolved problem	22
Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study	21
Experience of the Anaemia Mukt Bharat anaemia control programme in India	21
Patients receiving allogeneic haematopoietic stem-cell transplantation and clinical outcomes after early access to palliative care	21
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study	20
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM	20
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation t	20
Epistemic limitations of measurable residual disease in haematological malignancies	19
Lines of the haematology community	19
Intravenous iron for non-anaemic iron deficiency in pregnancy: a multicentre, two-arm, randomised controlled trial	19
Antifibrinolytics do not add to the benefits of platelet transfusion	19
Reducing toxic waste: improving toxicity capture in childhood cancer	18
Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China	18
Oleksandr Lysytsia: the war in Ukraine has changed everything about our lives	18
Making blood count	18
Improved survival and enhanced quality of life through anaemia correction in lower risk myelodysplastic syndromes: meaningful insights from an EUMDS Registry study	18
Mitapivat for treatment of pyruvate kinase deficiency	18
Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia	18
COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria	17
Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial	17
2025 ASH Annual Meeting	17
The effects of revised haemoglobin cutoffs on the global burden of anaemia	17
Incidence and prognosis of superficial vein thrombosis during pregnancy and the post-partum period: a Danish nationwide cohort study	17
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose e	17
Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, sing	17
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study	16
Sickle cell disease: a neglected health priority	16
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study	16
Correction to Lancet Haematol 2025; 12: e562–63	16
Immunochemotherapy for life-threatening haematological malignancies in pregnancy: a systematic review of the literature and cross-sectional analysis of clinical trial eligibility	16
Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial	16
Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial	15
Melflufen in multiple myeloma: the conclusion matters – Authors' reply	15

Correction to Lancet Haematol 2024; 11: e862–72	15
Long term strategies for individuals with sickle cell disease	15
Conditioning regimens for HSCT for patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukaemia	15
Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial	15
Reactivating hope for TP53-mutated acute myeloid leukaemia?	15
Iron deficiency anaemia—an ongoing challenge	14
Lallindra Gooneratne—maintaining treatment flow amid crisis	14
Sexually transmitted infections in the context of haematological malignancies	14
Correction to Lancet Haematol 2023; 10: e203–12	14
Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the U	14
Time to define and refine maintenance strategies in acute myeloid leukaemia	14
Long-term data from the REACH study testing hydroxyurea to treat sickle cell anaemia in children in sub-Saharan Africa	13
Treatment approaches for patients with TP53-mutated mantle cell lymphoma	13
The value of anti-CD30 CAR T cells in Hodgkin lymphoma	13
New hope, old challenges in myelodysplastic syndromes	13
Haemoglobin thresholds to define anaemia from age 6 months to 65 years: estimates from international data sources	13
An integrated approach to cardioprotection in lymphomas	13
Oncology service priorities for the new UK Government	13
Correction to Lancet Haematol 2025; 12: e808–22	12
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?	12
Renal colocalisation of Rosai-Dorfman-Destombes disease and secondary AA amyloidosis successfully treated with lenalidomide and dexamethasone	12
Concerns on perioperative anaemia management in the FIT trial	12
Isolated IgG4-related disease of the left maxillary antrum	12
Correction to Lancet Haematol 2025; 12: e128–37	12
Public health and programme development in sickle cell disease in Ghana: the legacy of Kwaku Ohene-Frempong	12
Inequalities in the career pathway for paediatric HSCT and cellular therapy physicians	11
Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?	11
Prehospital blood transfusion for haemorrhagic shock – Authors' reply	11
Correction to Lancet Haematol 2023; 10: e713–34	11
Virginia Abello Polo—a once-in-a-lifetime opportunity	11
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial	11
Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice	11
Fitusiran prophylaxis in severe haemophilia without inhibitors	11
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?	11
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study	11
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study	10
Mental health and psychological resilience in sickle cell disease	10
CAR T-cell therapies in China: rapid evolution and a bright future	10
Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial	10
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial	10
Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial	10
Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial	10
Overcoming the unmet need of Richter transformation: the use of pirtobrutinib	9
Correction to Lancet Haematol 2024; 11: e510–20	9
Haematopoietic stem-cell transplantation for sickle cell disease in low-income and middle-income countries: the experience in India	9
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomise	9
Environmental impact of haematology care—measurement and mitigation	9
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial	8
CAR T-cell therapy: navigating real-world challenges beyond clinical trials	8
Prioritising health equity alongside donation safety	8
Balancing toxicity and effectiveness in older adults with B-cell acute lymphocytic leukaemia	8
The dystopia of enforced childbirth	8
Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials	8
Establishing a sustainable academic point-of-care network for CAR T-cell therapy	8
Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome	8
Correction to Lancet Haematol 2024; 11: e38–50	8
Can ropeginterferon SURPASS resistance in essential thrombocythaemia?	8
A curious case of a neutrophilic horn	8
Maintaining MOMENTUM in myelofibrosis	8
48th Annual Meeting of the EBMT	8
Cristóbal Frutos: confronting treatment barriers	8
The role of conferences in tackling inequalities	8